European Union

AutoFull's C3 Pro Gaming Chairs Add Seat Cooling and Heating

LOS ANGELES – October 28, 2026 -- AutoFull's new C3 Pro Series gaming chairs are on sale in the United States now through the brand's website and Amazon, and the top model adds a ventilated, heated seat for long sessions at the desk.

Two models split essentials from extras

The series has two versions. The C3 Pro Standard covers the basics: adjustable lumbar support, lightning-inspired styling and everyday comfort. AutoFull aims it at first-time gaming chair buyers and people upgrading from a basic chair.

The C3 Pro Advanced adds active seat ventilation and heating, a larger upgraded seat and a retractable footrest.

Dual fans and graphene pads handle the temperature

Two fans in the Advanced seat circulate air to reduce heat buildup during extended play. Two graphene heating pads provide warmth when the room is cold. Users can pick from three ventilation levels and three heating levels.

Massage Gaming Chairs Hit Europe After ESL Katowice Debut

Katowice – October 13, 2026 -- AutoFull's M6 Ultra massage gaming chairs, used at every match of ESL Pro League Season 24, are now sold across Europe through autofull.com and Amazon, with regional fulfillment and warranty service in major EU markets.

Pro players sat in the M6 Ultra series for the whole tournament

The event, EPL Katowice 2026, ended on October 11 in Poland. AutoFull supplied its flagship M6 Ultra series, which it calls the world's first massage gaming chairs with cooling and heating seats.

The company became the Official Gaming Chair Partner of ESL Pro Tour in April 2026. The deal covers IEM, ESL Pro League and ESL Challenger League through 2027. Katowice was its fourth major stop this year, after IEM Rio, IEM Atlanta and IEM Cologne Major.

ADAC Warns: R134a Car AC Refills Set to Get Costlier and Scarcer

Munich – September 07, 2026 -- Owners of older cars running on the R134a refrigerant could soon face pricier and harder-to-schedule air conditioning maintenance, according to Germany's ADAC motoring club. Tighter EU rules are further restricting the use of R134a, while no widely available, legally approved alternative exists yet for the existing vehicle fleet.

New cars have banned R134a since 2017
New passenger vehicles have not been allowed to use R134a since 2017, and some workshops now offer conversions to the newer, more climate-friendly refrigerant R1234yf. However, existing R134a systems are generally not built for that swap, and ADAC says clear approvals and technical sign-offs for such conversions are still missing -- raising open questions about vehicle operating permits and liability.

Huawei Watch D3 Teased at ESC Congress 2026 as Next Blood Pressure Watch

Munich – September 07, 2026 -- Huawei gave an early preview of its next-generation ambulatory blood pressure watch, the HUAWEI WATCH D3, at the European Society of Cardiology Congress in Munich, ahead of its official unveiling at the Huawei Innovative Product Launch on September 2.

Huawei's wrist blood pressure tech dates back to 2021.

The company entered the sports and health sector in 2014, gradually adding heart rate monitoring, SpO2 tracking and ECG recording before launching the HUAWEI WATCH D in 2021 -- its first wrist-worn ambulatory blood pressure monitor, certified as a medical device in China and the European Union. The HUAWEI WATCH D2 followed in 2024 with 24-hour ambulatory blood pressure monitoring.

Ryanair Logs 15.8 Million Passengers in March as New Base and Routes Push Expansion Forward

SHERIDAN, WYOMING – April 14, 2026 – Ryanair has reported 15.8 million passengers for March 2026, a 5% increase on the same month a year earlier, as the airline group pressed ahead with a string of expansion moves. The traffic figures, released on April 2, arrived alongside the opening of a new four-aircraft base in Albania worth US$400 million and the inaugural flight of a brand-new Shannon–Rome summer 2026 route. Ryanair Holdings — the parent of five carriers including Buzz, Lauda, Malta Air, Ryanair, and Ryanair UK — currently carries around 208 million guests a year and has set a target of 300 million annual passengers by the financial year ending 2034. For budget travelers across Europe and beyond, the pace of growth signals more direct connections and continued competitive pricing on short-haul routes.

Volkswagen ID.3 Neo and ID. Cross Lead Electric Push as Brand Accelerates EV Lineup

SHERIDAN, WYOMING – April 12, 2026 – Volkswagen is pressing ahead with one of its most active electric vehicle rollouts in years, revealing the ID.3 Neo as the named successor to the ID.3 ahead of its world premiere in mid-April, while simultaneously debuting the near-production ID. Cross concept on the streets of Amsterdam as a preview of a compact SUV set to launch in Europe from autumn 2026 at a starting price of around 28,000 euros. The two announcements signal a deliberate push by the German automaker to deepen its electric portfolio across both the compact hatchback and affordable SUV segments, reaching buyers who have found earlier EV offerings either too expensive or too limited for daily use. Alongside these model introductions, Volkswagen has rolled out a significant software upgrade across the ID.4, ID.5, and ID.7, bringing new driver-assist features and a revised infotainment system that also apply to all new ID. models going forward.

EMA's #HealthNotHype Campaign Taps Social Media Creators to Counter GLP-1 Misinformation

SHERIDAN, WYOMING – April 12, 2026 – The European Medicines Agency has launched its first-ever social media campaign in partnership with content creators, deploying the hashtag #HealthNotHype to push verified information about GLP-1 receptor agonists directly into the platforms where misinformation about these medicines is most prevalent. The month-long campaign targets Instagram — chosen specifically because of the high volume of GLP-1 conversations circulating there — and recruits creators from seven EU member states who are predominantly healthcare professionals or nutrition experts. With obesity and diabetes rates climbing globally, and celebrity endorsements driving a surge of public interest in GLP-1 drugs well beyond clinical circles, the EMA is betting that credible voices embedded in social media feeds can counterbalance the spread of counterfeit products and dangerous misuse.

Lancia Corse España Enters Spanish Rally Superchampionship with Ypsilon Rally2 HF Integrale

SHERIDAN, WYOMING – April 12, 2026 – Spanish rally stages will see a Lancia factory-backed entry for the first time in roughly three decades, as Lancia Corse España deploys the Lancia Ypsilon Rally2 HF Integrale across the full 2026 S-CER (Spanish Rally Superchampionship) calendar. The campaign marks Lancia's formal return to organised national championship competition in Spain and runs parallel to the brand's wider re-entry into the World Rally Championship after a 30-year absence.

The team and its drivers

Lancia Corse España fields Asturian driver Diego Ruiloba alongside co-driver Ángel Vela as the programme's lead pairing. The duo finished as runners-up in the 2024 S-CER and subsequently competed as rookies in the 2025 WRC season under the Stellantis Motorsport development umbrella, giving them direct experience in top-level international rallying before returning to the domestic championship.

EMA launches #HealthNotHype campaign on safe use of GLP-1 medicines

20 June 2025: The European Medicines Agency has launched its first social media campaign with content creators to promote the safe and responsible use of GLP-1 receptor agonists, using the hashtag #HealthNotHype to broaden the reach of its public health messages.

Campaign launch and scope

EMA said the campaign is focused on raising awareness about the safe and responsible use of GLP-1 receptor agonists. These medicines were initially developed to treat type-2 diabetes, and some GLP-1 receptor agonists are now also indicated for weight management in people living with obesity and weight-related health conditions.

EMA launches #HealthNotHype campaign on safe GLP-1 medicine use with content creators

EMA, 2025: The European Medicines Agency has launched its first social media campaign involving content creators, aiming to raise awareness about the safe and responsible use of GLP-1 receptor agonists through the #HealthNotHype initiative.

Campaign launch and scope

The campaign focuses on medicines that were initially developed to treat type-2 diabetes. EMA said that some GLP-1 receptor agonists are now also indicated for weight management in people living with obesity and weight-related health conditions. The agency noted that these medicines are effective for patients, particularly against a backdrop of rising obesity and diabetes rates worldwide.